Agenus Inc
A biotech company that develops cancer treatments by rallying the body's own immune system, it makes antibody therapies that help immune cells recognize and attack tumors. Founded in 1994 as Antigenics by Dr. Garo Armen and Dr. Pramod Srivastava, it built early heat-shock cancer vaccines before renaming itself Agenus in 2011 to signal a broader mission. Its saponin-based QS-21 Stimulon adjuvant is the immune-boosting ingredient in vaccines like GSK's Shingrix shingles shot.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 13GPassive | 6% | 2.51M | Jul 27, 2026 |
| RA Capital Management, L.P. | 13GPassive | 9.9% | 4.34M | Jul 20, 2026 |
| Peter Kolchinsky | 13GPassive | 9.9% | 4.34M | Jul 20, 2026 |
| Rajeev Shah | 13GPassive | 9.9% | 4.34M | Jul 20, 2026 |
| RA Capital Healthcare Fund, L.P. | 13GPassive | 9.9% | 4.34M | Jul 20, 2026 |
| Raymond Debbane | 13GPassive | 9.99% | 4.53M | Jul 17, 2026 |
| Invus Public Equities, L.P. | 13GPassive | 8.8% | 3.97M | Jul 17, 2026 |
| Invus Public Equities Advisors, LLC | 13GPassive | 8.8% | 3.97M | Jul 17, 2026 |
| Invus Global Management, LLC | 13GPassive | 8.8% | 3.97M | Jul 17, 2026 |
| Siren, L.L.C. | 13GPassive | 8.8% | 3.97M | Jul 17, 2026 |